Physician profile
Brian A Quick
NPI 1518164557
$798.66
in general payments reported to CMS, 2019-2025
12 companies · $196 in 2025
The $196 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $66.22 · 2022: $92.24 · 2023: $385 · 2024: $59.83 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $640.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $429.49 | 2021-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $85.56 | 2023 | |
| Lilly USA, LLC | $66.68 | 2022-2023 | Mounjaro |
| Myriad Women'S Health, INC. | $43.78 | 2023 | Myrisk |
| Dexcom, INC. | $42.41 | 2021-2023 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $30.69 | 2023 | Farxiga |
| Averitas Pharma INC. | $20.28 | 2023 | Qutenza |
| Smith+Nephew, INC. | $18.23 | 2021 | |
| Astellas Pharma US INC | $16.52 | 2023 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $16.47 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.49 | 2023 | Jardiance |
| Alkermes, INC. | $13.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Quick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.